Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial Presented ByProf. Peter Calabresi, Johns Hopkins University, MD, USA TrialPhase 2, AFFINITY ConferenceECTRIMS 2021 9 December, 2021 14:12